The overall rate of HBV reactivation was evaluated in a population of 373 haematological stem cell transplant (HSCT) patients treated with lamivudine (LMV) if they were anti-HBc-positive/HBV-DNA-negative recipients or if they were HBV-negative recipients with an anti-HBc-positive donor.
Cerva, C., Colagrossi, L., Maffongelli, G., Salpini, R., Di Carlo, D., Malagnino, V., et al. (2016). Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor. CLINICAL MICROBIOLOGY AND INFECTION, 22(11), 946.e1-946.e8 [10.1016/j.cmi.2016.07.021].
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor
Salpini, R;Malagnino, V;PICARDI, ALESSANDRA;CUDILLO, LAURA;CERRETTI, RAFFAELLA;CANTONETTI, MARIA;ANDREONI, MASSIMO;PERNO, CARLO FEDERICO;ARCESE, WILLIAM;SVICHER, VALENTINA;SARMATI, LOREDANA
2016-07-27
Abstract
The overall rate of HBV reactivation was evaluated in a population of 373 haematological stem cell transplant (HSCT) patients treated with lamivudine (LMV) if they were anti-HBc-positive/HBV-DNA-negative recipients or if they were HBV-negative recipients with an anti-HBc-positive donor.| File | Dimensione | Formato | |
|---|---|---|---|
|
2016_Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis_ClinMicrobInfec_Cerva.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
374.74 kB
Formato
Adobe PDF
|
374.74 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
